Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202265 | 0.87 | HTR6 (0.67) | HTR6KCNH2HTR2C | |
| SCHEMBL1136470 | 0.78 | HTR6 (1.00) | HTR6 | |
| SCHEMBL6587972 | 0.72 | HTR6 (0.82) | HTR6HTR1AHTR2CHTR7HTR2B | |
| SCHEMBL27526625 | 0.71 | HTR6 (0.72) | HTR6KCNH2 | |
| SCHEMBL1136473 | 0.70 | HTR6 (0.78) | HTR6KCNH2HTR2C | |
| SCHEMBL1012930 | 0.70 | HTR6 (0.56) | HTR6 | |
| SCHEMBL5203694 | 0.70 | HTR6 (0.85) | HTR6 | |
| SCHEMBL4065470 | 0.69 | HTR6 (0.88) | HTR6 | |
| SCHEMBL5241267 | 0.68 | HTR6 (0.50) | HTR6KCNH2 | |
| SCHEMBL5203296 | 0.68 | HTR6 (0.66) | HTR6HTR1AHTR2CHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| CN-1257892-C | New indole derivatives with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN C (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | BEARD COLIN CHARLES (US) | 2004-12-09 | — | — | US | disclosed |
| CN-1527816-A | Novel indole derivatives having 5-HT 6 receptor affinity | - | 2004-09-08 | — | — | CN | disclosed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | disclosed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248902-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885KCNH2 1030/4885HTR1A 4/4885 |
| US-20050171118-A1 | New indole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885KCNH2 812/4885HTR1A 4/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885KCNH2 695/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.